



Intuitive Surgical Announces U.S. Clearance for da Vinci Xi Single-Site Instruments and Accessories

March 16, 2016 at 8:33 AM EDT

Leading second generation robotic technology enables surgeons to operate through single incision, resulting in virtually scarless surgery

SUNNYVALE, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG), the global leader in robotic-assisted minimally invasive surgery, today announced that the United States Food and Drug Administration has provided 510(k) clearance for the company's *da Vinci*® *Xi*® *Single-Site* instruments and accessories.

Intuitive Surgical's *Single-Site* technology enables surgeons to operate through a single incision in the patient's umbilicus during cholecystectomy, benign hysterectomy and salpingo-oophorectomy procedures.

"The *da Vinci Xi* was designed to seamlessly integrate advanced and future technologies and we are extremely pleased to further expand our line of product offerings with the clearance of *Single-Site* instruments and accessories," said Sal Brogna, Executive Vice President, Product Operations, Intuitive Surgical. "*Single-Site* technology adds great versatility to the *da Vinci Xi* by enabling both single port and multi-port surgery on a single system."

Since receiving FDA clearance in 2011, *Single-Site* technology for the *da Vinci Si* Surgical System has become the most prominent robotic-assisted single-port platform on the market. The *da Vinci Xi* Surgical System improves upon this platform with new technology, access, and functionality, including:

- **Improved Vision:** The *da Vinci Xi* 8 mm endoscope provides the surgeon a brighter, higher resolution view of the surgical field with integrated *Firefly*® fluorescence imaging to highlight specific tissues such as vessels and bile ducts.
- **Easier Setup:** A single-fin attachment system makes docking easier and faster with added *Single-Site* features like guided setup to improve OR team usability.
- **Great Patient Access:** The boom-mounted architecture of the *da Vinci Xi* Surgical System improves access around the patient with redesigned arms to provide greater range of motion.

The *Single-Site* product is immediately available for order, with rollout occurring in Q1 of 2016.

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (Nasdaq:ISRG), headquartered in Sunnyvale, Calif., is the global leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets the *da Vinci*® Surgical System.

About the *da Vinci* Surgical System

There are several models of the *da Vinci* Surgical System. The *da Vinci* Surgical Systems are designed to help surgeons perform minimally invasive surgery. *da Vinci* Systems are not programmed to perform surgery on their own. Instead, the procedure is performed entirely by a surgeon who controls the system. *da Vinci* Systems offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.

Important Safety Information

Serious complications may occur in any surgery, including *da Vinci* Surgery, up to and including death. Risks include, but are not limited to, injury to tissues and organs and conversion to other surgical techniques. If your doctor needs to convert the surgery to another surgical technique, this could result in a longer operative time, additional time under anesthesia, additional or larger incisions and/or increased complications. Individual surgical results may vary. Patients who are not candidates for non-robotic minimally invasive surgery are also not candidates for *da Vinci* Surgery. Patients should talk to their doctors to decide if *da Vinci* Surgery is right for them. Patients and doctors should review all available information on non-surgical and surgical options in order to make an informed decision. Please also refer to www.daVinciSurgery.com/Safety for Important Safety Information.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding regulatory clearances to market the *da Vinci Xi* System around the world. These forward-looking statements are necessarily estimates reflecting the best judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including those under the heading "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2015, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Statements using words such as "estimates," "projects," "believes," "anticipates," "plans," "expects," "intends," "may," "will," "could," "should," "would," "targeted" and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

CONTACT: Intuitive Surgical, Inc. (Nasdaq:ISRG)
Corporate Communications
408-523-7337
corpcomm@intusurg.com
<http://www.intuitivesurgical.com/>
<https://twitter.com/IntuitiveSurg>



Intuitive Surgical, Inc.